COPD: Journal of Chronic Obstructive Pulmonary Disease

COPD Foundation and DevPro Biopharma Join Forces to Develop Treatments for People with COPD and Related Lung Conditions

Retrieved on: 
Tuesday, March 23, 2021

The partnership aims to identify potential therapies for COPD and related lung conditions and to accelerate their development and regulatory approval.

Key Points: 
  • The partnership aims to identify potential therapies for COPD and related lung conditions and to accelerate their development and regulatory approval.
  • By joining forces, DevPro Biopharma will direct its expertise to the development of clinical programs to be conducted within the COPD Foundations network.
  • "This strategic alliance with DevPro Biopharma helps us build upon our improved understanding of the needs of patients across the spectrum of COPD and related lung conditions.
  • The COPD Foundation is the premier nonprofit organization dedicated to patients with COPD and related lung conditions.

PAOG Targets September 2021 to Introduce CBD Nutraceuticals to Market Co-Packed by ALKM and Marketed Through USMJ

Retrieved on: 
Tuesday, March 16, 2021

PAOG is building a comprehensive CBD nutraceuticals strategy to enhance its long-term CBD pharmaceutical strategy.

Key Points: 
  • PAOG is building a comprehensive CBD nutraceuticals strategy to enhance its long-term CBD pharmaceutical strategy.
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG is on track to introduce its first two CBD nutraceutical products in September of this year, 2021.
  • One CBD nutraceutical product will target the COPD market and the second will target the anxiety and depression market.

PAOG Announces Save The Date For CBD Nutraceuticals Expansion Update

Retrieved on: 
Wednesday, March 10, 2021

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG plans to develop and distribute its overall CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG CBD RELAX-RX Nutraceutical Plans To Co-Pack With ALKM And Market With USMJ Detailed In Update Scheduled Next Week

Retrieved on: 
Tuesday, March 9, 2021

RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.

Key Points: 
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
  • Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG CBD RELAX-RX Co-Packing with ALKM And Marketing with USMJ Detailed In Update Scheduled Next Week

Retrieved on: 
Tuesday, March 9, 2021

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).

Key Points: 
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • PAOG plans to develop and distribute its CBD nutraceuticals with Alkame Holdings, Inc. (OTC Pink: ALKM) as a copacker and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) as a distributor.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

Retrieved on: 
Monday, March 8, 2021

Sandusky, Ohio--(Newsfile Corp. - March 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025 .

Key Points: 
  • Sandusky, Ohio--(Newsfile Corp. - March 8, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025 .
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Pack Health & Physicians Health Plan of Northern Indiana Partner to Deliver Chronic Condition Support

Retrieved on: 
Thursday, February 25, 2021

BIRMINGHAM, Ala., Feb. 25, 2021 /PRNewswire/ -- Leading patient engagement platform Pack Health today announced its new partnership with Physicians Health Plan of Northern Indiana (PHP).

Key Points: 
  • BIRMINGHAM, Ala., Feb. 25, 2021 /PRNewswire/ -- Leading patient engagement platform Pack Health today announced its new partnership with Physicians Health Plan of Northern Indiana (PHP).
  • Pack Health and PHP's partnership focuses on supporting PHP's health plan members who are diagnosed with Type 2 Diabetes, Hypertension, Obesity, Prediabetes, or Chronic Obstructive Pulmonary Disease (COPD).
  • Pack Health will provide eligible members with one-on-one health coaching via phone, text, and email.
  • Pack Health is a digital health engagement platform that integrates evidence-based content, metrics, and devices to deliver highly personalized human-to-human support.

Vocalis Health's COVID-19 Screening Tool Successfully Validated in Large Clinical Study

Retrieved on: 
Wednesday, February 17, 2021

NEWTON, Mass., Feb. 17, 2021 /PRNewswire/ -- Vocalis Health ,a company pioneering AI-based vocal biomarkers in healthcare, today announced results of a clinical study conducted in collaboration with the Municipal Corporation of Greater Mumbai (MCGM) at theirNESCO COVID-19 Center to validate Vocalis Health's COVID-19 screening tool, VocalisCheck .

Key Points: 
  • NEWTON, Mass., Feb. 17, 2021 /PRNewswire/ -- Vocalis Health ,a company pioneering AI-based vocal biomarkers in healthcare, today announced results of a clinical study conducted in collaboration with the Municipal Corporation of Greater Mumbai (MCGM) at theirNESCO COVID-19 Center to validate Vocalis Health's COVID-19 screening tool, VocalisCheck .
  • In addition to the results of this study, Vocalis Health today announced that its COVID-19 screening tool, VocalisCheck, has obtained a CE mark.
  • VocalisCheck is the first device with CE mark approval for its medical intended use of screening for COVID-19.
  • Vocalis Health is currently focused on screening users for COVID-19 and on monitoring patients with chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF) and Pulmonary Hypertension (PH).

PAOG Targets $18 Billion Anxiety And Depression Treatment Market

Retrieved on: 
Thursday, February 11, 2021

PAOG plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach.

Key Points: 
  • PAOG plans to publish a multimedia presentation next week on the company's strategy to expand its nutraceutical product reach.
  • Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY).
  • RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No.
  • The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

PAOG Announces CBD Nutraceuticals Expansion Plan for $3.8 Billion Market Presentation Scheduled Next Week

Retrieved on: 
Monday, February 8, 2021

The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).

Key Points: 
  • The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).
  • The presentation is scheduled to be published next week on Tuesday, Feb 16th.
  • Last Thursday, PAOG revealed for the first time a broader nutraceutical development initiative with plans to produce nutraceuticals for additional applications.
  • The CBD nutraceutical market was valued at $3.8 billion in 2018 forecasted to grow at CAGR of over 18%.